Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the hemoglobin response rate in subjects with
anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRIT®)
every 2 weeks
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.